# Pregnancy and birth outcomes after SARS-CoV-2 vaccination

# in pregnancy

1

2

3

6

11

13

19 20 21

22

33

34

35 36

- 4 Regan N. Theiler, MD, PhD\*1, Myra Wick, MD, PhD1, Ramila Mehta3, Amy Weaver, MS3,
- 5 Abinash Virk, MD<sup>2</sup>, Melanie Swift, MD<sup>5</sup>
- 7 Mayo Clinic Department of Obstetrics and Gynecology, Division of Obstetrics
- 8 <sup>2</sup> Mayo Clinic Department of Medicine, Division of Infectious Disease
- 9 <sup>3</sup> Mayo Clinic Department of Quantitative Health Sciences
- <sup>5</sup> Mayo Clinic Division of Preventive, Occupational, and Aerospace Medicine
- 12 \*Corresponding author:
- 14 200 First St SE
- 15 Department of Obstetrics and Gynecology
- 16 Mayo Clinic
- 17 Rochester, MN 55905
- 18 Theiler.Regan@Mayo.edu

#### Disclosures:

- 23 Dr. Theiler has a know-how license and research funding from HeraMED
- Dr. Swift has funding from Pfizer via Duke University for the HERO Together vaccine safety registry.
- Dr. Virk reports being an inventor for Mayo Clinic Travel App interaction with Smart Medical Kit and Medical Kit for Pilgrims.
- 28 The other authors have declared no conflicts of interest

## **Acknowledgments:**

This work was funded in part by grant FP00085005-A1-03-S14 from the U.S. National Center for Translational Sciences. The funder did not participate in the study design, data collection, data analysis, or writing for publication.

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

**ABSTRACT** Background: SARS-CoV-2 infection during pregnancy is associated with significant maternal morbidity and increased rates of preterm birth. For this reason, COVID-19 vaccine administration in pregnancy has been endorsed by multiple professional societies including ACOG and SMFM despite exclusion of pregnant women from initial clinical trials of vaccine safety and efficacy. However, to date little data exists regarding outcomes after COVID-19 vaccination of pregnant patients. Study Design: A comprehensive vaccine registry was combined with a delivery database for an integrated healthcare system to create a delivery cohort including vaccinated patients. Maternal sociodemographic data were examined univariately for factors associated with COVID-19 vaccination. Pregnancy and birth outcomes were analyzed, including a composite measure of maternal and neonatal pregnancy complications, the Adverse Outcome Index. Results: Of 2002 patients in the delivery cohort, 140 (7.0%) received a COVID-19 vaccination during pregnancy and 212 (10.6%) experienced a COVID-19 infection during pregnancy. The median gestational age at first vaccination was 32 weeks (range 13 6/7-40 4/7), and patients vaccinated during pregnancy were less likely than unvaccinated patients to experience COVID-19 infection prior to delivery (1.4% (2/140) vs. 11.3% (210/1862)) P<0.001No maternal COVID-19 infections occurred after vaccination during pregnancy. Factors significantly associated with increased likelihood of vaccination included older age. higher level of maternal education, lower pre-pregnancy BMI, and use of infertility treatment for the current pregnancy. Tobacco or other substance use, Hispanic ethnicity, and higher gravidity were associated with a lower likelihood of vaccination. No significant difference in the composite adverse outcome (5.0% (7/140) vs. 4.9% (91/1862) P=0.95) or other maternal or neonatal

- 67 complications, including thromboembolic events and preterm birth, was observed in vaccinated
- 68 mothers compared to unvaccinated patients.
- 69 **Conclusions:** Vaccinated pregnant women in this birth cohort were less likely to experience
- 70 COVID-19 infection compared to unvaccinated pregnant patients, and COVID-19 vaccination
- 71 during pregnancy was not associated with increased pregnancy or delivery complications.
- 72 Significant sociodemographic disparities in vaccine uptake and/or access were observed among
- pregnant patients, and future efforts should focus on outreach to low-uptake populations.

### Introduction

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

In late 2020, the United States Food and Drug Administration (FDA) approved two mRNA vaccines, manufactured by Pfizer-BioNTech (BNT162b2) vaccine (Pfizer, Inc; Philadelphia, Pennsylvania) and Moderna (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts), for emergency use to prevent COVID-19 illness. Both vaccines were studied in large numbers of subjects during phase 3 randomized controlled trials, and both were shown to be highly effective at preventing COVID-19 infection in non-pregnant participants...<sup>1, 2</sup> Because none of the trials undertaken to gain FDA approval included pregnant or lactating women, use of the vaccines during pregnancy and lactation has been controversial.<sup>3</sup> During phase 1A of the vaccine rollout in the U.S., healthcare workers were the first population with access to vaccination, and thus many pregnant healthcare workers have received the vaccine. During phase 1B, teachers and other essential workers were vaccinated, adding to the population of reproductive age who were eligible for vaccination. Starting in December 2020, recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal-Fetal Medicine (SMFM), and the World Health Organization (WHO) endorsed availability of COVID-19 vaccination for pregnant women using a shared decisionmaking model with healthcare providers<sup>3, 4</sup>. COVID-19 disease during pregnancy is known to have severe manifestations in pregnant women compared to non-pregnant controls, with increased risk for maternal hospitalization, ICU admission, invasive ventilation, and death 5-7. Because of the known increased maternal risk of adverse outcomes with COVID-19 infection and the lack of theoretical or proven harm from the available vaccines, many patients have opted for vaccination despite limited safety and efficacy data for the vaccines in pregnant patients. The vaccines are thought to be effective when administered during pregnancy, as antibody production occurs rapidly after administration. However, immune alterations that occur in pregnancy may theoretically decrease the vigor of

cell-mediated immune responses to infection. <sup>2,8</sup> Neutralizing antibody response is highly reassuring and suggests robust efficacy during pregnancy with possible benefit to the neonate. Recently published COVID-19 vaccine surveillance data from the Centers for Disease Control and Prevention's (CDC) voluntary V-SAFE registry including 3958 subjects vaccinated during pregnancy suggests that pregnant women do not have increased rates of adverse vaccine reactions compared to control patients, and that patients do not report increases in adverse pregnancy outcomes compared to non-pregnant women<sup>9</sup>. The V-SAFE data, however, are limited to patient-reported reactions and pregnancy events and subject to selection bias, and lack of validated primary data supporting conclusions. For this reason, vaccine efficacy should be demonstrated in pregnancy using infectious outcomes as well. Adding to the available data, we present pregnancy outcomes from a Mayo Clinic Health System delivery cohort delivering during the first months of vaccine availability.

#### Methods

A comprehensive vaccine registry was created, capturing COVID-19 vaccine administrations, manufacturer, and patient identifying information from Mayo Clinic vaccination sites as well as other sites across the states of Minnesota and Wisconsin. The vaccination registry was then linked to the Mayo Clinic delivery registry, which contains detailed maternal and neonatal outcomes from all births within the Mayo Clinic Health System. The delivery registry data is derived directly from elements in the electronic medical record and all fields have been validated manually during development. Creation of the registries and subsequent analysis was performed in accordance with human subjects regulations under approval by the Mayo Clinic Institutional Review Board.

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

Criteria for study inclusion included all patients age 16-55 years old with a delivery event between December 10, 2020, and April 19, 2021 at a Mayo Clinic hospital. Minnesota patients who opted out of use of their medical records for research were excluded from the study if their delivery occurred in Minnesota. COVID infection during pregnancy was defined as a positive SARS-CoV-2 RT-PCR test documented in the medical record between the dates of conception and delivery, and was stratified by first trimester (2-13 6/7 weeks gestation), second trimester (14 0/7- 27 6/7 weeks gestation) and third trimester (≥28 weeks gestation) infection. All COVID infections regardless of temporal relationship to vaccine are included in Table X. For purposes of assessing vaccine side effects and pregnancy outcomes, vaccinated individuals are defined as those receiving any dose of vaccine during pregnancy. For purposes of assessing vaccine effectiveness, fully vaccinated was defined as >14 days after the final dose of vaccine. The composite outcome, the adverse outcome index (AOI) was calculated as a composite of any of the following events during the delivery hospitalization: maternal death, uterine rupture, unplanned maternal ICU admission, return to the operating room within 72 hours of delivery, postpartum hemorrhage with blood transfusion, third or fourth degree laceration, intrapartum fetal or unexpected neonatal death (within 72hrs), hypoxic ischemic encephalopathy, five minute Apgar <7, admission to the NICU with birthweight >2500g, or neonatal birth trauma. All qualifying events were verified by chart review. The AOI for a group of patients was calculated as the number of patients with one or more identified adverse events divided by the total number of deliveries, multiped by 100. A woman with multiple gestations was counted as a single delivery. A modified AOI was also calculated by not considering third- and fourth-degree perineal laceration as an adverse event. Additional outcomes measured included thromboembolism or stroke within 4 weeks before or after delivery, gestational hypertensive disorders diagnosed up to 72 hours after delivery, low and very low birth weight, preterm birth (< 37 weeks gestation), length of postpartum maternal stay after delivery, and stillbirth.

The primary outcome in this study was AOI. The AOI was 4.9% within the Mayo Clinic Health System for calendar year 2019. This study was designed with 80% power, using a two-sided chi-square test with a type I error rate of 0.05, to detect a difference in AOI of 4.9% vs. at least 11.5% between those without versus with a COVID-19 vaccine during pregnancy, based on 1862 and 140 patients in the two groups.

Data management and statistical analysis was performed using SAS version 9.4 (SAS institute, Cary, NC, USA). Comparisons between groups were evaluated using the chi-square test or Fisher's exact test for non-ordered categorical variables, the Wilcoxon rank sum test for ordinal variables, and the two-sample t-test for continuous variables. A 95% confidence interval (CI) for the difference in the AOI between two groups was calculated based on exact methods for a binomial parameter. All calculated p-values were two-sided and p-values less than 0.05 were considered statistically significant.

### Results

Of 2002 total patients, 140 received at least one dose of a COVID-19 vaccine prior to delivery, and 200 experienced a COVID-19 infection during pregnancy. Among the vaccinated patients, one received the Janssen COVID-19 (Ad.26.COV2.S) vaccine (Janssen Biotech, Inc, a Janssen Pharmaceutical company, Johnson & Johnson; New Brunswick, New Jersey), 12 received the Moderna vaccine, and 127 received the Pfizer-BioNTech vaccine (**Table 1**). The median estimated gestational age (EGA) at initiation of the of the vaccination series was 32 (range 13 6/7-40 4/7) weeks gestation, and patients vaccinated during pregnancy were less likely than unvaccinated patients to experience COVID-19 infection (1.4% vs. 4.5%, P<0.01) prior to delivery. Completed vaccination was documented at a median EGA of 35 2/7 weeks (range 17 1/7-44 1/7), with 73.6% of patients completing vaccination prior to delivery.

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

Sociodemographic factors (Table 1) positively associated (p<0.05) with maternal vaccination included older maternal age at delivery, with a median of 32 (range 20-40) vs. 30 (range 16-48) years of age, P<0.0001). Vaccinated patients were also more educated, P trend <0.0001, and a history of infertility treatment was also noted more frequently among vaccinated patients, with 6/131 (4.3%) vs. 14/1862 (0.8%) having a history of infertility therapy, (P=0.0018). Factors negatively associated (p<0.05) with vaccination included Hispanic ethnicity (6/140 or vs. 173/1825, P=.0323), current smoking (0/140 vs.196/1862, P<0.0001), current illicit drug use (0/140 vs. 56/1862, P=0.0301), higher gravidity, and higher pre-pregnancy body mass index (P trend= 0.0036). Race and rates of comorbid conditions including pre-gestational diabetes, chronic hypertension, and asthma were not significantly associated with vaccination status. Patients vaccinated during pregnancy were less likely than unvaccinated patients to experience COVID-19 infection prior to delivery (1.4% (2/140))vs. 11.3% (210/1861)), P= <0.001), with the two infections occurring in the vaccinated group prior to vaccine administration. In the unvaccinated group, COVID-19 infections occurred during each trimester of pregnancy, with 26 infections in the first trimester, 84 during the second trimester, and 100 in the third trimester (**Table 2**). The composite pregnancy outcome, AOI, did not differ by maternal vaccination status, with rates of 5.0% (7/140) vs. 4.9% (91/1862) in the vaccinated and unvaccinated groups (95% CI for difference in proportions, -3.6% to 3.6%). No maternal or early neonatal deaths occurred in the cohort. Mode of delivery, gestational age at delivery, neonatal birth weight, thromboembolic events, and rates of gestational hypertensive disorders also did not significantly differ between groups. Additional comparison between COVID-19 infected, non-vaccinated patients (n=210) and vaccinated patients without a history of COVID-19 infection (n=138) did not show any difference among the pregnancy outcomes examined in the cohort, but the study was not sufficiently powered to detect a difference in these outcomes (Appendix Table A2). Among the unvaccinated patients, pregnancy and birth outcomes did not significantly differ

between those with (n=210) versus without (n=1652) a COVID-19 infection during pregnancy (Appendix Table A2).

## **Discussion**

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

While COVID-19 infection in pregnancy has been associated with adverse maternal and neonatal outcomes in multiple studies, outcomes following COVID-19 vaccination during pregnancy remain largely unknown. The current cohort adds evidence of vaccine safety and efficacy after administration to pregnant women during the third trimester. Given the absence of infection in any vaccinated patients after the first dose administration (incidence rate ratio of zero and vaccine efficacy of one) with a short observation period, our ability to estimate vaccine efficacy is limited for this cohort. No patterns of adverse maternal or neonatal outcomes were observed in this cohort of patients who were vaccinated under the FDA emergency use authorizations, and fewer vaccinated women experienced COVID-19 infection during the pregnancy. The current study largely represents outcomes after third trimester vaccination, but patients who received the vaccine during the late first through second trimesters and delivered preterm are represented in this data set as well. The absence of an increase in preterm births in the cohort thus suggests that vaccination is unlikely to increase preterm birth rates, but analysis of outcomes from currently ongoing pregnancies will be needed to confirm this finding. This study reveals some sociodemographic factors associated with vaccine access and/or uptake in the pregnant population. Vaccination eligibility during the timeframe analyzed was limited to healthcare workers, the elderly, and teachers or other essential workers. For this reason, we cannot discern whether sociodemographic differences in vaccination status are due to vaccine hesitancy or eligibility for vaccination, but we do observe socioeconomic disparity

between those who received vaccination during gestation and those who did not. Outreach to the under-represented populations of pregnant patients should be a focus of future education and vaccination efforts. Strengths of this study include the inclusion of comprehensive population-level vaccine registry data in combination with a validated, all-inclusive delivery database including births at multiple community and teaching hospitals across two states As the data were extracted from the primary medical record it is not subject to recall bias. Limitations of this analysis include the small percentage of non-white subjects in this geographic region, the potential for confounding due to the observational nature of the study, as well as the data currently available being biased toward those vaccinated later in gestation and skewed toward the population in the United States healthcare workforce. Finally, only two COVID-19 infections occurred in the vaccinated group early in pregnancy, so they may be a group who had lower baseline exposure compared to the unvaccinated group. Our findings should give clinicians confidence that COVID-19 vaccination during pregnancy is effective in preventing maternal SARS-CoV-2 infection, and that no pattern of adverse maternal or neonatal outcomes is evident during pregnancy, adding to the growing body of evidence supporting the safety of COVID vaccines in pregnant women. Additional studies will be needed to examine differences in rare adverse birth outcomes, as well as outcomes following vaccination during early pregnancy. Outreach to under-represented populations of pregnant patients should be a focus of future education and vaccination efforts.

#### References

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

245 1. BADEN LR, EL SAHLY HM, ESSINK B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
246 New England Journal of Medicine 2021;384:403-16.

- 247 2. POLACK FP, THOMAS SJ, KITCHIN N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 2020;383:2603-15.
- 249 3. ADHIKARI EH, SPONG CY. COVID-19 Vaccination in Pregnant and Lactating Women. JAMA 250 2021;325:1039-40.

244

266

- Vaccinating Pregnant and Lactating Patients Against COVID-19*Practice Advisory*: American
   College of Obstetrics and Gynecology, 2021.
- VILLAR J, ARIFF S, GUNIER RB, et al. Maternal and Neonatal Morbidity and Mortality Among
   Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort
   Study. JAMA pediatrics 2021.
- ADHIKARI EH, MORENO W, ZOFKIE AC, et al. Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection. JAMA network open 2020;3:e2029256-e56.
- LOKKEN EM, HUEBNER EM, TAYLOR GG, et al. Disease severity, pregnancy outcomes, and maternal
   deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection
   in Washington State. American Journal of Obstetrics and Gynecology 2021.
- 262 8. COLLIER A-RY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA 2021.
- 264 9. SHIMABUKURO TT, KIM SY, MYERS TR, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. New England Journal of Medicine 2021:NEJMoa2104983-NEJMoa83.

# Table 1. Demographics of the study population

COVID Vaccine				
	No	Yes	Total	P-value
	(N=1862)	(N=140)	(N=2002)	
Maternal Age at Delivery				<.0001 <sup>1</sup>
N	1862	140	2002	
Mean (SD)	30.0 (5.23)	31.8 (3.72)	30.1 (5.16)	
Median	30	32	30	
Range	16.0, 48.0	20.0, 40.0	16.0, 48.0	
<b>Race</b> , n (%)				0.1299 <sup>4</sup>
Asian	89 (4.8%)	6 (4.3%)	95 (4.7%)	
Black or African American	99 (5.3%)	3 (2.1%)	102 (5.1%)	
Not Disclosed	146 (7.8%)	3 (2.1%)	149 (7.4%)	
White	1528 (82.1%)	128 (91.4%)	1656 (82.7%)	
vviiice	1323 (02.170)	120 (31.770)	2000 (02.770)	
Ethnicity, n (%)				0.0323 <sup>4</sup>
Hispanic or Latino	173 (9.3%)	5 (3.6%)	178 (8.9%)	
Not Hispanic or Latino	1651 (88.7%)	132 (94.3%)	1783 (89.1%)	
Unknown	38 (2.0%)	3 (2.1%)	41 (2.0%)	
Education, yrs., n (%)				<.00014
<12	70 (4.7%)	0 (0.0%)	70 (4.3%)	1,0001
12-16	1218 (81.9%)	70 (53.4%)	1288 (79.6%)	
>16	199 (13.4%)	61 (46.6%)	260 (16.1%)	
Missing	375	9	384	
Current Smoker, n (%)	196 (10.5%)	0 (0.0%)	196 (9.8%)	<.0001 <sup>2</sup>
Illicit Drug Use, n (%)	56 (3.0%)	0 (0.0%)	56 (2.8%)	0.0301 <sup>3</sup>
Gravidity, n (%)				0.00654
1	546 (29.3%)	56 (40.0%)	602 (30.1%)	0.0003
2	519 (27.9%)	34 (24.3%)	553 (27.6%)	
3	350 (18.8%)	29 (20.7%)	379 (18.9%)	
4+	447 (24.0%)	21 (15.0%)	468 (23.4%)	
	(=)	(		
Pre-Pregnancy BMI, n (%)				0.00364
<25	573 (39.6%)	70 (56.5%)	643 (41.0%)	
25-30	409 (28.3%)	21 (16.9%)	430 (27.4%)	
30-35	226 (15.6%)	15 (12.1%)	241 (15.4%)	

35-40	139 (9.6%)	14 (11.3%)	153 (9.7%)	
40+	99 (6.8%)	4 (3.2%)	103 (6.6%)	
Missing	416	16	432	
Pre-Gestational Diabetes, n (%)	11 (0.6%)	2 (1.4%)	13 (0.6%)	0.2292 <sup>3</sup>
Pre-Gestational Hypertension, n (%)	64 (3.4%)	6 (4.3%)	70 (3.5%)	0.6295³
Asthma, n (%)	206 (11.1%)	15 (10.7%)	221 (11.0%)	0.8989 <sup>2</sup>
Infertility Treatment, n (%)	14 (0.8%)	6 (4.3%)	20 (1.0%)	0.0018 <sup>3</sup>
Multiple Gestation, n (%)				0.6826 <sup>3</sup>
Singleton	1840 (98.8%)	138 (98.6%)	1978 (98.8%)	
Twins	22 (1.2%)	2 (1.4%)	24 (1.2%)	
GBS Test Result, n (%)				0.7453 <sup>4</sup>
Negative	1283 (68.9%)	94 (67.1%)	1377 (68.8%)	
Not Tested	274 (14.7%)	20 (14.3%)	294 (14.7%)	
Positive	305 (16.4%)	26 (18.6%)	331 (16.5%)	
<sup>1</sup> T-test p-value; <sup>2</sup> Chi-Square p-value; <sup>3</sup> Fisher's Exact Test p-value; <sup>4</sup> Wilcoxon Rank Sum p-value				

# Table 2. Maternal and delivery outcomes after vaccination during pregnancy

271

	COVID Vaccine			
	No (N=1862)	Yes (N=140)	Total (N=2002)	P-value
Covid-19 Infection During Pregnancy, n (%)				0.00044
None	1652 (88.7%)	138 (98.6%)	1790 (89.4%)	
Trimester 1	26 (1.4%)	0 (0.0%)	26 (1.3%)	
Trimester 2	84 (4.5%)	2 (1.4%)*	86 (4.3%)	
Trimester 3	100 (5.4%)	0 (0.0%)	100 (5.0%)	
Adverse Outcomes Index (AOI), n (%)	91 (4.9%)	7 (5.0%)	98 (4.9%)	0.95241
AOI Excluding Laceration, n (%)	55 (3.0%)	5 (3.6%)	60 (3.0%)	0.60713
Hypoxic, Ischemic Encephalopathy, n (%)	1 (0.1%)	0 (0.0%)	1 (0.0%)	1.00³
Uterine Rupture, AOI, n (%)	1 (0.1%)	0 (0.0%)	1 (0.0%)	1.00³
Unplanned ICU Admission, n (%)	2 (0.1%)	1 (0.7%)	3 (0.1%)	0.1956 <sup>3</sup>
Birth Trauma, n (%)	11 (0.6%)	0 (0.0%)	11 (0.5%)	1.00³
Return to OR, n (%)	6 (0.3%)	1 (0.7%)	7 (0.3%)	0.3985³
NICU admit > 2500g, n (%)	11 (0.6%)	1 (0.7%)	12 (0.6%)	0.5821 <sup>3</sup>
5 Minute Apgar <7, n (%)	38 (2.0%)	3 (2.1%)	41 (2.0%)	0.7617 <sup>3</sup>
Hemorrhage with transfusion, n (%)	5 (0.3%)	1 (0.7%)	6 (0.3%)	0.3531³
3 <sup>rd</sup> or 4 <sup>th</sup> degree laceration, n (%)	37 (2.0%)	2 (1.4%)	39 (1.9%)	1.00³
Mode of Delivery, n (%)				0.6518 <sup>1</sup>
Spontaneous Vaginal	1238 (66.5%)	89 (63.6%)	1327 (66.3%)	
Operative Vaginal	69 (3.7%)	7 (5.0%)	76 (3.8%)	
Cesarean	555 (29.8%)	44 (31.4%)	599 (29.9%)	

Gestational Age Delivery, n (%)				0.7028 <sup>1</sup>
37+	1703 (91.5%)	127 (90.7%)	1830 (91.4%)	
32-36 6/7	134 (7.2%)	10 (7.1%)	144 (7.2%)	
24-31 6/7	21 (1.1%)	2 (1.4%)	23 (1.1%)	
<24	4 (0.2%)	1 (0.7%)	5 (0.2%)	
Length of Stay				0.2744 <sup>2</sup>
Mean (SD)	1.8 (0.76)	1.9 (0.87)	1.8 (0.76)	
Median	2	2	2	
Range	0.0, 8.0	1.0, 7.0	0.0, 8.0	
Quantitative Blood Loss > 1000mL, n (%)	57 (3.1%)	6 (4.3%)	63 (3.1%)	0.4452 <sup>3</sup>
Transfusion, n (%)	241 (12.9%)	25 (17.9%)	266 (13.3%)	0.1198 <sup>3</sup>
Thromboembolism, n (%)	2 (0.1%)	0 (0%)	2 (0.1%)	1.00³
Stroke, n (%)	1 (0.1%)	0 (0.0%)	1 (0.0%)	1.00 <sup>3</sup>
Eclampsia / Pre-Eclampsia (+/- 72 hours of Delivery), n (%)	23 (1.2%)	1 (0.7%)	24 (1.2%)	1.00³
Gestational Hypertension, n (%)	225 (12.1%)	19 (13.6%)	244 (12.2%)	0.6038 <sup>1</sup>
Low Birth Weight (<2500g), n (%)	121 (6.5%)	11 (7.9%)	132 (6.6%)	0.53211
Very Low Birth Weight (<1500g), n (%)	21 (1.1%)	3 (2.1%)	24 (1.2%)	0.2332 <sup>3</sup>
StillBirth, n (%)	6 (0.3%)	0 (0.0%)	6 (0.3%)	1.00³
*Infections occurred prior to first dose of				
<sup>1</sup> Chi-Square test; <sup>2</sup> Kruskal-Wallis test; <sup>3</sup> F	isher's Exact test			